Richard Kim

Richard Kim currently serves as the Chief Commercial Officer at Cristcot, leading the launch and commercialization efforts for a Phase III therapy for ulcerative colitis. Prior to this role, Richard held the position of Chief Commercial Officer at Avadel Pharmaceuticals, overseeing the development of a commercial team and the successful launch of LUMRYZ in 2023. Experience includes significant roles at Intercept Pharmaceuticals as President of U.S. Commercial and Global Marketing and at Bristol-Myers Squibb, where leadership extended over various functions, including the Global Commercialization of Hepatitis C products. Richard began professional career in sales and marketing at Schering Plough and possesses a Bachelor of Science in Chemistry from the University of Alberta.